Н.Л. Цапаева, Н.В. Тарашкевич, Е.В. Миронова, П.Ф. Черноглаз, Д.И. Юрлевич
Учреждение образования «Белорусский государственный медицинский университет», г. Минск, Учреждение здравоохранения «1 городская клиническая больница», г. Минск, Учреждение здравоохранения «9 городская клиническая больница», г. Минск
Цель Исследовать клинический статус и состояние микроциркуляции у пациентов ИБС с неполной реваскуляризацией миокарда в отдаленном периоде первичного ЧКВ и изучить возможность использования препарата ранолазин у этой категории пациентов.
ключевые слова: чрезкожное коронарное вмешательство, полная и неполная реваскуляризация миокарда, микроциркуляция, ранолазин

для цитирования: Н.Л. Цапаева, Н.В. Тарашкевич, Е.В. Миронова, П.Ф. Черноглаз, Д.И. Юрлевич. Возможности антиангинальной терапии у пациентов с неполной реваскуляризацией миокарда в отдаленном периоде первичного чрескожного коронарного вмешательства. Неотложная кардиология и кардиоваскулярные риски. 2018, Т. 2. № 2. С. 392-396

Antianginal treatment options of patients with incomplete myocardial revascularization in the long-term period after primary percutaneous coronary intervention
N.L. Tsapaeva, N.V. Tarashkevich, E.V. Mironova, Chernoglaz, D.I. Yurievich
The aim of the present study is to investigate the clinical and microcirculatory status and possibilities of ranolazin treatment in patients with in complete myocardial revascularization in long -term follow -up after primary percutaneous coronary intervention.
keywords: percutaneous coronary intervention, complete and incomplete myocardial revascularization, microvascular dysfunction, ranolazin

for references: N.L. Tsapaeva, N.V. Tarashkevich, E.V. Mironova, Chernoglaz, D.I.Yurlevich. Antianginal Treatment Options of Patients with Incomplete Myocardial Revascularization in the Long-Term Period after Primary Percutaneous Coronary Intervention. Emergency Cardiology and CardiovascularRisks. 2018, vol. 2, № 2, pp. 392-396

[1] Wijns W., Kolh P., Danchin N., Di Mario C., Falk V., Folliguet T., Garg S., Huber K., James S., Knuuti J., Lopez-Sendon J., Marco J., Menicanti L., Ostojic M., Piepoli M.F., Pirlet C., Pomar J.L., Reifart N., Ribichini F.L., Schalij M.J., Sergeant P., Serruys P.W., Silber S., Sousa Uva M., Taggart D. [Collaborators 58] Guidelines on myocardial revascularization. Eur Heart J, 2010, vol. 31, № 20, pp. 2501-555. doi: 10.1093/eurheartj/ehq277.
[2] Widimsky P., Fajadet J Danchin N., Wijns W. «Stent 4 Life». Targeting PCI at all who will benefit the most. A joint project between EAPCI, Euro-PCR, EUCOMED and the ESC Working Group on Acute Cardiac. Eurolntervention, 2009, vol. 4, № 5, pp. 555-557.
[3] Safley D.M., House J.A., Marso S.P., Grantham J.A., Rutherford B.D. Im provem ent in survival following successful percutaneous coronary intervention of coronary chronic total occlusions: variability by target vessel. JACC Cardiovasc Interv, 2008, vol. 1, № 3, pp. 295-302
[4] Meier B., Luethy P., Finci L., Steffenino G.D., Rutishauser W. Coronary wedge pressure in relation to spontaneously visible and recruitable collaterals. Circulation, 2008, vol.75, № 5, pp. 906-913.
[5] Sambuceti G., Marzilli M., Mari A., Marini C., Schluter M., Testa R., Papini M., Marraccini P., Ciriello G., Marzullo P., L’Abbate A. Coronary m icrocirculatory vasoconstriction is heterogeneously distributed in acutely ischemic myocardium. Am J Physiol Heart Circ Physiol, 2005, vol. 288, № 5, pp. H2298-H2305.
[6] Safley D., House J. Marso S. (2008) / Improvement in survival following successful percutaneous coronary intervention of coronary chronic total occlusions: variability by target vessel. JACC Cardiovasc Interv., vol. 1(3), pp. 295-302.
[7] Tsapaeva N.L., Chernoglaz P.F., Yurlevich D.I., Mironova E.V., Kolb M.V., Zhuk O.I. Otdalennye rezul’taty endovaskulyarnoy revaskulyarizazii miokarda u pazientov s ostrym koronarnym sindromom [Long-term effectiveness of endovascular myocardil revascularization in patients with acute coronary syndrome]. Kardiologiya vBelarusi, vol. 9, № 3, pp. 614­619. (in Russian).
[8] Tsapaeva N.L., Tarashkevich N.V., Mironova E.V., Jn Shojan, Konstantinova E.E., Chernoglaz P.F., Yurlevich D.I. M ikrozirkulyatornaya disfunkziya u pazientov s nepolnoy revaskulyarizaziey miokarda v otdalennom periode pervichnogo chrezkozhnogo koronarnogo vmeshatel’stva (vozmozhnosti diagnostiki i lecheniya) [M icrovascular dysfunction in patients with incomplete myocardial revascularization in the long-term period of primary percutaneous coronary intervention (diagnosis and treatment opportunities)]. Neotlozhnaya kardiologiya i kardiovaskulyarnye riski, 2017, vol. 1, № 1, pp. 125-130. (in Russian).
[9] Prasad A., Rihal C.S., Lennon R.J., Wiste H.J., Singh M., Holmes D.R.Jr. Trends in outcomes after percutaneous coronary intervention for chronic totalocclusions: a 25-year experience from the mayo clinic. J A m Coll Cardiol, 2007, vol. 49, № 15, pp. 1611-1618.
[10] Aslam S., Gray D. Ranolazine (Ranexa) in the treatment of chronic stable angina. Adv Ther, 2010, vol. 27, № 4, рр. 193-201.
[11] Letienne R., Vie B., Puech A., Vieu S., Le Grand B., John G.W. Evidence that ranolazine behaves as a weak beta1- and beta2- adrenoceptor antagonist in the cat cardiovascular system. N aunyn Schmiedebergs Arch Pharmacol, 2001, vol. 363, № 4, рр. 464-471.
[12] Estacion M., Waxman S.G., Dib-Hajj S.D. Effects of ranolazine on wildtype and mutant hNav1.7 channels and on DRG neuron excitability. M ol Pain, 2010, vol. 6, № 35, рр. 35. doi: 10.1186/1744-8069-6-35.
[13] Karpov Yu.A. Antianginal’naya terapiya: fokus na ranolazin [Antianginal Therapy: Focus on Ranolazine]. Consilium medicum, 2013, № 5, pp. 26­30. (in Russian).
[14] Chaitman B.R., Pepine C.J., Parker J.O., Skopal J., Chumakova G., Kuch J., Wang W., Skettino S.L., W olff A.A. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: A randomized controlled trial. JAMA, 2004, vol. 291, № 3, рр. 309-316.
Формат файла: pdf (1.4 Мб)